1. DеGennes L, Deltour G. Aldosterone, a new adrenocortical steroid. Presse Med. 1954;62(85): 1751-2.
2. Iudaev N.A. New steroid hormone of the adrenal cortex aldosterone (electrocortin)]. Problemy Endokrinologii i Gormonoterapii. 1955;1(1):118-20. (In Russ.).
3. Kagawa C.M., Van Arman C.G. Effects of cortisone and hydrocortisone on sodium excretion in adrenalectomized rats. Proc Soc Exp Biol Med. 1957;94(4):683-6.
4. Kagawa C.M., Sturtevant F.M., Van Arman C.G. Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone. J Pharmacol Exp Ther. 1959;126(2):123-30.
5. Bolte E., Verdy M., Marc-Aureleet J. et al. Studies on New Diuretic Compounds: Spirolactone and Chlorothiazide. Can Med Assoc J. 1958;79(11):881–8.
6. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensinaldosterone system. Circulation. 1991;83(6):1849-65.
7. Giljarevskij S.R., Golshmid M.V., Kuz'mina I.M. The role of aldosterone-receptor antagonists in prevention and treatment of heart and kidney disease: actuality and promises. Russkiy Meditsinskiy Zhurnal.
8. ;23:1689-98. (In Russ.).
9. Sabbadin C., Calo L.A., Armanini D. The story of spironolactones from 1957 to now: from sodium balance to inflammation. G Ital Nefrol. 2016;33Suppl 66:33.
10. Sica D.A. Spironolactone: an old friend rediscovered. J Clin Hypertens (Greenwich). 2006;8(7):467-9.
11. Funder J.W. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control. 2013;6:129-38.
12. Funder J.W. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinol. 2006;147:5564-7.
13. Zannad F. Aldosterone and heart failure. Eur Heart J. 1995;16 Suppl N:98-102.
14. Ramires F.J., Mansur A., Coelho O. et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85(10):1207-11.
15. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35.
16. Mareev V.Ju. Guidelines for the rational management of heart failure. Consilium Medicum. 1999;3:13842. (In Russ.).
17. Zannad F., Alla F., Dousset B. et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES) Rales Investigators. Circulation. 2000;102:2700-6.
18. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-17.
19. Vizzardi E., Nodari S., Caretta G., et al. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. The American Journal of the Medical Sciences. 2014;347(4):271-6.
20. Muldowney J.A. 3rd, Schoenhard J.A., Benge C.D. The clinical pharmacology of eplerenone. Expert Opin Drug Metab Toxicol. 2009;5(4):425-32.
21. Pitt B., Williams G., Remme W. et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15(1):79-87.
22. Zannad F., McMurray J.J., Krum H. et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1):11-21.
23. Podzolkov V.I., Rodionov A.V. Primary hyperaldosteronism: diagnosis and treatment. Arterialnaya Hypertenziya. 2004;10(2):109-14. (In Russ.).
24. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925-38.
25. Parthasarathy K.H., Menard J., White W.B. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29:980-90.
26. Williams B., MacDonald T.M., Morant S. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059-68.
27. Adams M., Bellone J.M., Wright B.M., et al. Evaluation and pharmacologic approach to patients with resistant hypertension. Postgrad Med. 2012;124(1):74-82.
28. Oliveras A., Armario P., ClaraA., et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens. 2016;34(9):1863-71.
29. Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol. 2011;17(10): 1237-48.
30. Verma D., Thompson J., Swaminathan S. Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function. Proc Natl Acad Sci USA. 2016;113(13):3609-14.
31. Dinh Q.N., Young M.J., Evans M.A., et al. Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor. Brain Res. 2016;1637: 146-53.
32. Bender S.B., DeMarco V.G., Padilla J., et al. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension. 2015;65(5):1082-8.
33. Esposito C.T., Varahan S., Jeyaraj D.et all. Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. J Cardiovasc Electrophysiol. 2013; 24(7):806-12.
34. Вeygui F., Vicaut E., Ecollan P., et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am Heart J. 2010;160:642-8
